Abstract :
[en] Repeated mild traumatic brain injury is of growing interest regarding public and sporting safety and is thought to have greater adverse or cumulative neurological effects when compared with single injury. While epidemiological links between repeated traumatic brain injury and outcome have been investigated in humans, exploration of its mechanistic substrates has been largely undertaken in animal models. We compared acute neurological effects of repeat mild traumatic brain injury (n = 21) to that of single injury (n = 21) and healthy controls (n = 76) using resting-state functional MRI and quantified thalamic functional connectivity, given previous identification of its prognostic potential in human mild traumatic brain injury and rodent repeat mild traumatic brain injury. Acute thalamocortical functional connectivity showed a rank-based trend of increasing connectivity with number of injuries, at local and global scales of investigation. Thus, history of as few as two previous injuries can induce a vulnerable neural environment of exacerbated hyperconnectivity, in otherwise healthy individuals from non-specialist populations. These results further establish thalamocortical functional connectivity as a scalable marker of acute injury and long-term neural dysfunction following mild traumatic brain injury.
Funding text :
Seventh Framework Programme (FP7) Grant 602150 (CENTER-TBI, D.K.M. and E.A.S.), Medical Research Council (MRC) Doctoral Training Programme Grant MR N013433-1 (R.E.W.), Stephen Erskine Fellowship at Queens’ College, Cambridge (E.A.S.), Canadian Institute for Advanced Research grant RCZB/072 RG93193 (E.A.S. and D.K.M.), British Oxygen Professorship of the Royal College of Anaesthetists (D.K.M.), National Institute for Health and Care Research Senior Investigator Awards (D.K.M.) and Medical Research Council (MRC) (D.K.M.).
Competing interests
D.K.M. reports grant support from the National Institute for Health Research (UK), Medical Research Council (UK), Canadian Institute for Advanced Research and the European Union. He is in receipt of collaborative research grant funding with Lantmannen AB, GlaxoSmithKline Ltd and Cortirio Ltd and personal fees from Calico LLC, GlaxoSmithKline Ltd, Lantmannen AB and Integra Neurosciences. All other authors declare that they have no competing interests.
Scopus citations®
without self-citations
1